<?xml version='1.0' encoding='utf-8'?>
<document id="27262758"><sentence text="Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study."><entity charOffset="29-40" id="DDI-PubMed.27262758.s1.e0" text="daclatasvir" /><entity charOffset="45-55" id="DDI-PubMed.27262758.s1.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.27262758.s1.e0" e2="DDI-PubMed.27262758.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27262758.s1.e0" e2="DDI-PubMed.27262758.s1.e1" /></sentence><sentence text="HCV recurrence remains a major issue in the liver transplant field, as it has a negative impact on both graft and patient survival" /><sentence text=" The purpose of this study was to investigate the efficacy and safety of treating HCV recurrence with sofosbuvir (SOF) and daclatasvir (DCV) combination therapy"><entity charOffset="102-112" id="DDI-PubMed.27262758.s3.e0" text="sofosbuvir" /><entity charOffset="114-117" id="DDI-PubMed.27262758.s3.e1" text="SOF" /><entity charOffset="123-134" id="DDI-PubMed.27262758.s3.e2" text="daclatasvir" /><pair ddi="false" e1="DDI-PubMed.27262758.s3.e0" e2="DDI-PubMed.27262758.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27262758.s3.e0" e2="DDI-PubMed.27262758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27262758.s3.e0" e2="DDI-PubMed.27262758.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27262758.s3.e1" e2="DDI-PubMed.27262758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27262758.s3.e1" e2="DDI-PubMed.27262758.s3.e2" /></sentence><sentence text="" /><sentence text="From October 2013 to March 2015, 559 liver recipients were enrolled in the prospective multicentre France REcherche Nord&amp;Sud Sida-hiv HÃ©patites (ANRS) Compassionate use of Protease Inhibitors in viral C Liver Transplantation cohort" /><sentence text=" We selected 137 patients with an HCV recurrence receiving SOF and DCV, whatever the genotype or fibrosis stage"><entity charOffset="59-69" id="DDI-PubMed.27262758.s6.e0" text="SOF" /></sentence><sentence text=" The use of ribavirin and the duration of therapy were at the investigator's discretion"><entity charOffset="12-21" id="DDI-PubMed.27262758.s7.e0" text="ribavirin" /></sentence><sentence text=" The primary efficacy end point was a sustained virological response (SVR) 12weeks after the end of treatment" /><sentence text="" /><sentence text="The SVR rate 12weeks after completing treatment was 96% under the intention-to treat analysis and 99% when excluding non-virological failures" /><sentence text=" Only two patients experienced a virological failure" /><sentence text=" The serious adverse event (SAE) rate reached 17" /><sentence text="5%" /><sentence text=" Four patients (3%) stopped their treatment prematurely because of SAEs" /><sentence text=" Anaemia was the most common AE, with significantly more cases in the ribavirin group (56% vs"><entity charOffset="70-79" id="DDI-PubMed.27262758.s15.e0" text="ribavirin" /></sentence><sentence text=" 18%; p&lt;0" /><sentence text="0001)" /><sentence text=" A slight but significant reduction in creatinine clearance was reported"><entity charOffset="39-49" id="DDI-PubMed.27262758.s18.e0" text="creatinine" /></sentence><sentence text=" No clinically relevant drug-drug interactions were noted, but 52% of patients required a change to the dosage of immunosuppressive drugs" /><sentence text="" /><sentence text="Treatment with SOF plus DCV was associated with a high SVR12 and low rates of serious adverse events among liver recipients with HCV recurrence"><entity charOffset="15-24" id="DDI-PubMed.27262758.s21.e0" text="SOF" /></sentence><sentence text="" /><sentence text="The recurrence of hepatitis C used to be the first cause of graft failure in infected liver transplanted recipients" /><sentence text=" Our study demonstrates the great efficacy of one combination of new all-oral direct-acting antiviral, sofosbuvir and daclatasvir, to treat the recurrence of hepatitis C on the graft"><entity charOffset="103-113" id="DDI-PubMed.27262758.s24.e0" text="sofosbuvir" /><entity charOffset="118-129" id="DDI-PubMed.27262758.s24.e1" text="daclatasvir" /><pair ddi="false" e1="DDI-PubMed.27262758.s24.e0" e2="DDI-PubMed.27262758.s24.e0" /><pair ddi="false" e1="DDI-PubMed.27262758.s24.e0" e2="DDI-PubMed.27262758.s24.e1" /></sentence><sentence text=" Ninety-six per cent of recipients were cured" /><sentence text=" The safety profile of this combination seemed to be good, especially no relevant drug-drug interaction with immunosuppressive drugs" /><sentence text="" /></document>